Charles River to Acquire Vigene Biosciences for $292.5M

 Charles River to Acquire Vigene Biosciences for $292.5M

Charles River to Acquire Vigene Biosciences for $292.5M

Shots:

  • Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5M based on future performance
  • The transaction is expected to be close in Q3’21. The acquisition will allow Charles River to boost its gene therapy capabilities in the high-growth, value-added cell, and gene therapy CDMO sector
  • Vigene is expected to improve Charles River’s reported revenue growth rate by ~50 basis points in 2021. The acquisition complements Charles River’s existing non-clinical development and manufacturing portfolio

Click here to­ read full press release/ article | Ref: Business Wire | Image: Pharma Advancement

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post